

# ESMO Breast Cancer 2019 Industry Satellite Symposium

Addressing ongoing clinical challenges: how do we optimize patient outcomes with CDK4/6 inhibition in HR+/HER2- breast cancer?

FRIDAY 3 MAY 2019 | 18:30 – 19:30 CEST | BERLIN HALL, MARITIM HOTEL BERLIN, GERMANY

## INVITATION

Dear Colleague,

On behalf of the faculty, it is my pleasure to invite you to join us for a satellite symposium (ACCME-accreditation submitted) taking place during the ESMO Breast Cancer 2019 Congress. During this interactive programme, we will discuss the differentiating factors affecting selection and sequencing of CDK4/6 inhibitors in patients with HR+/HER2- advanced breast cancer. We will also explore practical considerations for effective adverse event management during breast cancer treatment.

During the session, we will welcome your comments and questions to ensure our discussions are relevant to your practice. I am sure you will agree that there are several important issues to discuss in this engaging and interactive programme.

We hope that you can join us as we continue our endeavours to optimize outcomes in the treatment of HR+/HER2- breast cancer.



With regards,

*Stephen R Johnston*

**PROFESSOR STEPHEN JOHNSTON** (Chair)  
The Royal Marsden NHS Trust, UK

## AGENDA

### 18:30 Introduction and welcome – where are we now?

*Prof. Stephen Johnston*

### 18:35 Challenge 1. How do we optimize patient selection and treatment sequencing for HR+/HER2- advanced breast cancer therapy in the era of CDK4/6 inhibition?

Presentation with panel discussion  
Questions from the audience

*Prof. Nadia Harbeck and faculty*

### 18:45 Challenge 2. How do we optimize AE management with CDK4/6 inhibitors?

Presentation with panel discussion  
Questions from the audience

*Prof. Mario Campone and faculty*

### 18:55 Clinical challenges in action. What would you do in our interactive case scenarios?

Interactive case studies with audience voting

*Prof. Stephen Johnston and faculty*

### 19:10 Moving forward in early breast cancer: future application of CDK4/6 inhibitors?

Presentation with panel discussion  
Questions from the audience

*All faculty*

### 19:30 Summary from the Chair and meeting close

*Prof. Stephen Johnston*